<DOC>
	<DOCNO>NCT00861042</DOCNO>
	<brief_summary>The primary objective trial ass tolerability safety long-term SPM 927 administration subject diabetic neuropathy .</brief_summary>
	<brief_title>An Open-label follow-on Trial Assess Long-term Safety Efficacy Oral SPM 927 Subjects With Diabetic Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subject successfully complete previous trial SPM 927 diabetic neuropathy , investigator 's opinion , would benefit longterm administration SPM 927 . Subject stable , good fair diabetic control ( HbA1c ≤10 % ) . Subject condition cause neuropathic pain least severe diabetic pain , i.e . peripheral arteriovascular disease . Subject receive treatment seizure . Subject amputation relate diabetes , toe amputation . Subject major skin ulcer . Subject clinically significant ECG abnormality . Subject expect take study : TCAs , mexiletine hydrochloride , lidoderm patch , tramadol , AEDs , dextromethorphan , opioids , capsaicin , skeletal muscle relaxant , benzodiazepine overthecounter medication centrally act property . Subject laboratory value outside normal range judge investigator clinically significant . Subject liver function test ( AST , ALT , alkaline phosphatase , total bilirubin , GGT ) ≥ 2x ULN Visit 1 . At Visit 1 , subject impair renal function , i.e. , creatinine clearance ( ClCr ) low 60 mL/min .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Lacosamide , Vimpat®</keyword>
</DOC>